IBB
iShares Biotechnology ETF
NasdaqGMUSDEQUITY
DELAYED
Buy
+24/100
Last price
203.34
▲ 0.24 (0.12%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
202.00
Prev close
203.10
Day high
205.81
Day low
201.13
Volume
1.48M
Market cap
—
P/E (TTM)
—
52W range
149.09 – 217.12
Day trading desk
Gap from prior close
-0.54%
Prior close 203.10
VWAP
203.90
-0.28% from price
Relative volume
—
—
Session range
2.32%
201.13 – 205.80
Position in range
47%
Mid range
ATR (14D)
4.42
2.17% of price
Prior day high
210.24
PDH
Prior day low
201.48
PDL
Bid / ask spread
—
Quote not published
Session volume
1.45M
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.42%
-5.3%
1M
-1.92%
-3.4%
3M
+3.04%
-0.4%
6M
+18.32%
+3.3%
YTD
+20.48%
+6.5%
1Y
+35.09%
+19.4%
3Y
+68.55%
-13.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on IBB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
207.70
-2.10% from price
SMA 20
206.39
-1.48% from price
SMA 50
204.72
-0.67% from price
SMA 100
192.14
+5.83% from price
SMA 200
181.62
+11.96% from price
EMA 12
206.57
-1.56% from price
EMA 26
206.47
-1.52% from price
EMA 50
203.20
+0.07% from price
RSI (14)
44.7
Neutral
MACD (12,26,9)
0.10
Hist -0.80
ATR (14)
4.42
2.17% of price
Realised vol 30D
20.4%
Annualised
Bollinger upper
212.54
20, 2σ
Bollinger lower
200.23
20, 2σ
50 / 200 cross
Golden
204.72 vs 181.62
Trend bias
Above 200
+11.96%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.76
Less volatile than market
Correlation to SPY
0.45
Loosely linked
Realised vol 30D
20.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-9.7%
Peak to trough
Max drawdown 5Y
-35.8%
Peak to trough
ATR 14
4.42
2.17% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
24/7 Wall St. · 1d ago
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher
24/7 Wall St. · 1d ago
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
24/7 Wall St. · 2d ago
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
24/7 Wall St. · 6d ago
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
24/7 Wall St. · 7d ago
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
24/7 Wall St. · 7d ago
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
24/7 Wall St. · 12d ago
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
24/7 Wall St. · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.